Vicente H. Gracias, M.D.

• Instructor of Surgery and Trauma
• Surgical Critical Care Fellow
• University of Pennsylvania
• Philadelphia, PA

Obviously medications similar to cymbalta order trileptal online from canada, a patient with life-threatening clinical signs (repeated seizures treatment brachioradial pruritus discount 300 mg trileptal, respiratory depression medications 6 rights purchase generic trileptal, dysrhythmias) will be classified as severe medications for fibromyalgia order trileptal 600 mg on line. A proper risk assessment of the exposure medicine naproxen discount trileptal 150 mg otc, which includes close collaboration with a poison control center, may help estimate the risk for any specific patient. Rarely, an antidote may either amend or prevent the apparition of toxic symptoms related to a poison. This relates to a high extraction ratio and a high extracorporeal clearance (see earlier). To decide whether blood purification is indicated for a specific poisoning, the clinician must anticipate which benefits are expected from the procedure; some exposures can cause death. In other situations, the poisoning itself may not cause irreversible injury, but the patient may be subjected to prolonged coma and immobilization, requiring mechanical ventilation and tight surveillance in the intensive care unit. In the absence of any clinical outcome data, studies should demonstrate, at a minimum, significant drug removal. Because time is usually a concern, a temporary catheter is preferred, using ultrasonographic guidance to limit complications and ensure patency. The dialyzer or hemofilter should have a molecular size cutoff above that of the poison that needs to be removed. In patients at high risk for bleeding, saline flushes can be substituted for heparin. Blood, dialysate, and effluent flow: They should all be maximized according to the capabilities of the machine to maximize clearance. Bicarbonate, sodium, calcium, and magnesium levels need to be adjusted in the dialysate bath (or replacement fluid) to the requirement of the poisoned patient to avoid dangerous imbalances. It is also recommended that periodic measurement of serum biochemistry be performed and the content of the dialysate be adapted if needed. Logistics and clinical status may require transfer of the patient to the intensive care unit. In the former case, the elevation of the serum concentration comes at the expense of a concomitant decrease in poison concentration from the toxic compartments, a phenomenon that would therefore not be worrisome but rather even desirable,69 and that would present an added opportunity to remove more poison with a subsequent treatment. In the situation of ongoing absorption of the poison, the increase in serum concentration can cause recurrence of toxic symptoms. To address rebound, clinicians may choose to repeat a session, switch to a continuous therapy, or extend the intermittent therapy longer than the typical 4- to 6-hour treatment duration without added risk. The catheter should remain in place until the physician is convinced that additional sessions are unnecessary. In fact, the drugs or poisons that are most commonly responsible for poisoning-related fatalities. The remainder of this chapter focuses on the clinical characteristics of intoxicants that may be responsive to extracorporeal removal. In its pure form, ethylene glycol is colorless, odorless, syrupy, and sweet-tasting, which makes it attractive to young children. It is commonly found in antifreeze, radiator fluid, solvents, hydraulic brake fluid, deicing solutions, detergents, lacquers, and polishes. It is a light, volatile, flammable liquid with a distinctive odor similar to ethanol. The solvents that contain methanol include windshield- or glass-cleaning solutions, enamels, printing solutions, stains, dyes, varnishes, thinners, fuels, and antifreeze additives for gasoline. It is commonly found in "rubbing alcohol," skin lotion, hair tonics, aftershave lotion, denatured alcohol, solvents, cements, cleaning products, and the manufacturing process of acetone and glycerin. Although the parent alcohols themselves cause minor toxicity (usually no more than moderate inebriation), their metabolites can induce life-threatening toxicity. Ethylene glycol, methanol, and isopropanol are all small molecules, unbound to protein, and distribute in total body water (Vd = 0. Intoxication of these alcohols occurs rapidly after exposure and usually results from oral ingestion, although inhalation of vapors71,72 and cutaneous absorption have been reported, especially in children. Metabolic acidosis is caused by the formation and accumulation of glycolic acid, glycoaldehyde, and glyoxylic acid. The remainder of the toxicity of ethylene glycol is precipitated by systemic calcium oxalate deposition in various tissues such as the kidneys. Methanol follows zero-order kinetics elimination at low serum concentration and firstorder kinetics at higher concentration, which may relate to pulmonary clearance. As the cellular pH falls, inhibition of cytochrome c oxidase by formic acid is increased, exacerbating the acidosis, eventually leading to cell hypoxia and cell death. Approximately 80% is metabolized to acetone via alcohol dehydrogenase, and the remainder is eliminated unchanged in urine, with very small amounts excreted by the lungs. Cerebral edema, nystagmus, ataxia, myoclonic jerks, and hyporeflexia have been described. New onset of cranial nerve defects (in particular the seventh) should make a clinician suspect ethylene glycol ingestion. Gastrointestinal irritation may lead to vomiting, hematemesis, and aspiration pneumonia. During this stage, calcium oxalate crystals deposit in the vasculature, myocardium, and lungs. Methanol intoxication should always be suspected in a patient presenting with neurologic, visual, and gastrointestinal symptoms in the presence of high anion gap metabolic acidosis with increased osmolal gap. Methanol can produce Parkinson-like syndrome by damage to putamen and subcortical white matter of the basal ganglia. Visual changes are the hallmark of methanol poisoning and usually occur 6 to 30 hours after exposure, depending on whether ethanol is co-ingested; symptoms may include blurred vision (flashes or snowstorm), central scotoma, impaired papillary response to light, decreased visual acuity, photophobia, visual field defect, and progression to complete blindness. The diagnosis of isopropanol overdose should be suspected in any patient with altered sensorium, a "fruity" acetone breath, an increased osmolal gap without an increase in anion gap, and the presence of acetonemia or acetonuria in the absence of hyperglycemia, glycosuria, or acidosis. Isopropanol is also a gastrointestinal tract irritant and can cause nausea, vomiting, gastritis, and abdominal pain. Finally, isopropanol is directly toxic to myocytes and can induce severe hypotension, which is the strongest predictor of mortality in isopropanol overdose. Other systemic findings include hypoglycemia from impaired gluconeogenesis, hypothermia, and hemolytic anemia. This estimation can be monitored serially during admission and especially during dialysis, when precise serum levels are unavailable. An osmolal gap over 25 mOsm/kg suggests the presence of ethylene glycol, methanol, ethanol, isopropanol, propylene glycol, or acetone. Urinalysis can provide supporting evidence of ethylene glycol exposure; calcium oxalate crystals (monohydrate and dihydrate forms) may be present in the urine sediment and are birefringent when viewed under polarized light. These crystals appear 4 to 8 hours after ingestion and are found in approximately 50% of patients. The dihydrate form, which is octahedral, or tent shaped, is present only under conditions of high urinary calcium and oxalate levels, therefore more specific for ethylene glycol poisoning. Urine that fluoresces under Wood lamp illumination is another unique feature of ethylene glycol poisoning. For up to 6 hours after ingestion, sodium fluorescein can be detected in the urine. Characteristic test findings of isopropanol exposure include increased osmolality, the absence of metabolic acidosis (except if lactic acidosis is present), ketonemia, ketonuria, and normoglycemia. Acetonemia or acetonuria can be suspected by a positive sodium nitroprusside reaction in plasma or urine. Low concentration of serum ketones 2 hours after isopropanol ingestion (in the absence of alcohol dehydrogenase inhibition) generally excludes substantial ingestion. Initial management, as for all poisonings, is directed toward stabilization and providing appropriate supportive care, which may include airway management, volume resuscitation, seizure management, and vasopressors. Acidemia should be corrected with the administration of intravenous sodium bicarbonate,107 which enhances deprotonation of acid metabolites, making them less likely to penetrate end-organ tissues (retina and kidney) and more likely to be excreted by the kidneys. An initial intravenous bolus (1 to 2 mEq/kg), followed by a perfusion if necessary, should be given to maintain an arterial pH no less than 7. Asymptomatic hypocalcemia is not routinely treated in the setting of ethylene glycol poisoning because it can potentially exacerbate calcium oxalate crystal formation and deposition. Pyridoxine, thiamine, and magnesium are co-factors in the metabolism of ethylene glycol, and their supplementation is recommended in patients who may be malnourished. The suggested dose is 50 mg intravenously every 4 hours for five doses and then once daily. The cornerstone of the treatment of ethylene glycol or methanol poisoning is to delay their metabolism into toxic metabolites by use of antidotal agents (ethanol or fomepizole), which inhibit the actions of alcohol dehydrogenase. Serum concentration of ethylene glycol above 20 mg/dL or methanol above 20 mg/dL 2. Documented recent (hours) ingestion of toxic amount of ethylene glycol or methanol and osmolal gap higher than 10 mOsm/L 3. A history or strong clinical suspicion of ethylene glycol or methanol poisoning, and at least two of the following: arterial pH less than 7. The intravenous formulation has the advantages of immediate bioavailability and avoiding gastrointestinal distress. Assumes initial ethanol concentration is zero; dose is independent of chronic drinking status. When dialysis parameters are optimized (see earlier), clearance of alcohols and metabolites can reach 250 mL/min. For example, patients who are poisoned with ethylene glycol, but who neither are acidotic nor have renal impairment, may be treated with fomepizole alone, whatever the concentration of ethylene glycol. Assuming a methanol half-life of 54 hours under fomepizole,112 a patient with an initial methanol concentration of 320 mg/dL would need to be hospitalized 9 days for methanol concentration to be considered safe (under 20 mg/dL). Dialysis might therefore be instituted to reduce hospitalization costs and antidote requirement for patients poisoned with either ethylene glycol or methanol. In these cases, alcohol dehydrogenase inhibition should not be used alone but in association with some form of extracorporeal purification. Serum ethylene glycol or methanol concentration above 50 mg/dL if fomepizole is not used 2. The use of heparin should be minimized or altogether avoided in methanol-poisoned patients, because they are at higher risk for intracerebral hemorrhage. Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ratios of adenosine diphosphate to adenosine triphosphate and adenosine monophosphate to adenosine triphosphate in cells. Salicylic acid is used as a topical keratolytic agent and wart remover; bismuth subsalicylate (Pepto-Bismol; 236 mg of salicylate per 15 mL) is used for reflux disease, and methyl salicylate (oil of wintergreen; 98% salicylate; 1 teaspoon contains 7 g of salicylates) is used for pain relief and as a flavoring agent. In acute overdose, bezoar formation and pylorospasm may delay appearance of symptoms. Salicylate and aspirin are rapidly hydrolyzed by the liver to salicylic acid and subsequently oxidized or conjugated to glucuronic acid or glycine. Salicylic acid is filtered at the glomerulus, actively secreted in the proximal tubule, and reabsorbed passively in the distal tubules. These modifications result in a major increase in the elimination halflife (>30 hours). This provides the rationale for urinary alkalinization to enhance elimination of salicylates. Acute ingestions over 150 mg/kg usually present with mild-to-moderate toxicity; over 300 mg/kg, patients usually have severe clinical features, and exposures over 500 mg/kg are potentially lethal. Acute salicylate ingestion often causes nausea and vomiting as a result of gastritis and direct stimulation of the chemoreceptor trigger zone in the medulla. A variety of acid-base abnormalities may occur with salicylate poisoning, but the classical finding is mixed respiratory alkalosis and high anion gap metabolic acidosis. Salicylate stimulates the respiratory center in the brainstem independently of the aortic and carotid chemoreceptors, leading to an early fall in carbon dioxide pressure and respiratory alkalosis. Cerebral edema, perhaps secondary to capillary leak, may also play a role in alterations in mental status. Hypoglycemia occurs later with heightened cellular energy demand and uncoupling of oxidative phosphorylation. Symptoms in this setting are often more prominent than after an acute ingestion for a same salicylate concentration; such patients are often misdiagnosed as having delirium, encephalopathy, or fever of unknown origin, and they have a high mortality. An elevated anion gap with concomitant respiratory alkalosis should prompt confirmation of salicylate exposure. Bedside urine ferric chloride testing can confirm the presence of salicylate exposure but is not specific for poisoning. Quantitative serum salicylate levels can generally be obtained rapidly in many centers. Because absorption may be erratic or prolonged, serial measurements (every 2 to 4 hours) are required. The magnitude of the level is less important in patients with significant symptoms because treatment will be initiated regardless. In these cases the salicylate level is most useful for monitoring the effectiveness and determining the duration of therapy. The Done nomogram, which was an attempt to correlate salicylate levels with toxicity, is no longer in clinical use because of its poor predictive value. Endotracheal intubation should therefore be performed only if absolutely necessary and by an experienced clinician to avoid prolonged periods of apnea, during which many deaths are reported. As mentioned previously, alkalinization will drive salicylate to be dissociated, which will prevent both its diffusion through the blood-brain barrier and its tubular reabsorption (ion trapping). Because Kd is a logarithmic function, small changes in urine will have a large effect on salicylate elimination. Because an alkaline urine cannot be produced in the presence of severe hypokalemia (kidney reabsorption of potassium occurs via the H+-K+-exchange pump in the distal tubule), potassium levels should be monitored and aggressively corrected. The first article ever published on diffusion-based techniques showcased removal of salicylates from animal subjects in 1913 by Abel and colleagues. Extracorporeal purification should be maintained until salicylate levels are below 20 mg/dL. Lithium is a 7-Da monovalent cation, orally administered as a carbonate (capsule) or citrate (liquid).

The beneficial effects of kidney transplantation on life expectancy medications mothers milk thomas hale discount trileptal uk, quality of life medicine to induce labor cheap trileptal 150 mg line, and medical expenses are greater than those associated with maintenance dialysis medicine for diarrhea buy trileptal with american express. In this declaration medications or drugs buy trileptal 150 mg with visa, Islamic theologians recognized that brain death was irreversible and could be used to declare a person legally dead medicine you can overdose on generic 600 mg trileptal amex, thereby making it permissible to disconnect that person from mechanical life-support systems. This declaration was preceded in 1982 by a resolution of the Islamic Council in Saudi Arabia that permitted the use for transplantation of organs from both living and deceased donors. With regard to living related donors, Bulka argued that organ donation is permissible, because the danger to the donor is minimal, but it is not obligatory. In fact, in 2006 Saudi Arabia had the highest reported rate of living-donor kidney transplantation worldwide at 32 procedures pmp, followed by Jordan (29 procedures pmp), Iceland (26 procedures pmp), Iran (23 procedures pmp), and the United States (21 procedures pmp). According to Nöel, the report by Horvat and colleagues probably included "transplant tourism" activity because it incorporated data on kidney transplantation in Saudi patients from living unrelated donors that was performed in other countries. However, the ratio of deceased donors to living donors is not constant, according to the annual reports of the Israeli National Transplant Center. This change was mainly due to a substantial parallel increase in braindead kidney donation (2. This practice is often called "commercial kidney transplantation" or "organ tourism" because the donor sells his or her kidney for a certain amount of money. The outcome of this meeting was the "Declaration of Istanbul on Organ Trafficking and Transplant Tourism," which suggested that strategies to increase the donor pool and encourage legitimate, lifesaving transplantation programs be developed by countries to prevent organ trafficking, transplant commercialism, and transplant tourism. Consequently, Israel has both increased organ donations from living and deceased sources and has reduced the number of transplant candidates seeking transplantation abroad (from 150 in 2006 to 41 in 2013). In most of the commercial transplantation programs, induction therapy is routinely given to reduce the frequency of acute graft rejection so that the recipient can be discharged early after the transplantation surgery. For economic reasons, several countries prefer to prescribe azathioprine and the cheap generic forms of cyclosporine instead of mycophenolate mofetil and tacrolimus. Hyperimmune globulins and plasmapheresis are rarely used because both are expensive. Tuberculosis in the graft kidney tends to manifest as granulomatous interstitial nephritis. The diagnosis is usually made on kidney biopsy or after nephrectomy in recipients, who often present with fever of unknown origin and deteriorating graft function. Therefore increasing the dose of calcineurin inhibitors and frequent monitoring of their circulating levels are mandatory in such cases. Its fascinating geography is combined with rich national histories, cultures, and resources. Well-conducted epidemiologic cohort studies are urgently needed, and regional and national registries must be established as sources of transparent and accurate data. In addition, these efforts should also focus on the special needs of refugees in countries where humanengendered and natural disasters have occurred. The entire international nephrology community agrees that improving existing diagnostic methods and establishing preventive strategies for the detection and treatment of kidney diseases at the earliest possible stage is of utmost importance, especially in countries with limited resources or health expenditures. Mahdavi-Mazdeh M, Zamyadi M, Nafar M: Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran. Matzner Y, Abedat S, Shapiro E, et al: Expression of the familial Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures. Livneh A, Langevitz P, Zemer D, et al: Criteria for the diagnosis of familial Mediterranean fever. Manukyan G, Petrek M, Tomankova T, et al: Colchicine modulates expression of pro-inflammatory genes in neutrophils from patients with familial Mediterranean fever and healthy subjects. Ter Haar N, Lachmann H, Ozen S, et al: Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Rafiq H: Palestinian health system after three years of the Intifada-survival, development, or both Suleiman K, Ghattas B, Makhoul C: the health status of the Palestinian Arab community in Israel in relation to the Jewish community of Israel. Commentary: the growing risk factors for noncommunicable diseases in the Arab world. Forzley M: Advancing the health of Arab Americans: key points to obtaining resources and establishing programs focused on special populations. Abboud O: Incidence, prevalence, and treatment of end-stage renal disease in the Middle East. Managing cardiovascular risk barriers to optimal health outcomes in the Arab American patient. Denktas S, Koopmans G, Birnie E, et al: Ethnic background and differences in health care use: a national cross-sectional study of native Dutch and immigrant elderly in the Netherlands. Zimmerman C, Kiss L, Hossain M: Migration and health: a framework for 21st century policy-making. Al-Homrany M: Epidemiology of acute renal failure in hospitalized patients: experience from southern Saudi Arabia. Balushi F, Khan S, Riyami D, et al: Acute kidney injury in a teaching hospital in Oman. Duzova A, Bakkaloglu A, Kalyoncu M, et al: Etiology and outcome of acute kidney injury in children. Al-Malki H, Sadek M, Rashed A, et al: Acute renal failure in the State of Qatar: presentation and outcome. Sitprija V: Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis. Bernieh B, Al Hakim M, Boobes Y, et al: Pattern of acute renal failure in a tertiary hospital in the United Arab Emirates. Hatamizadeh P, Najafi I, Vanholder R, et al: Epidemiologic aspects of the Bam earthquake in Iran: the nephrologic perspective. Kantarci G, Vanholder R, Tuglular S, et al: Acute renal failure due to crush syndrome during Marmara earthquake. Iraj N, Saeed S, Mostafa H, et al: Prophylactic fluid therapy in crushed victims of Bam earthquake. Khogali M: Health and disease in a changing Arab world 2000/2025/2050: global, environmental, and climate change and emerging diseases. Alhyas L, McKay A, Majeed A: Prevalence of type 2 diabetes in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review. El-Reshaid W, El-Reshaid K, Kapoor M, et al: Chronic renal disease in Kuwaiti nationals: a prospective study during the past 4 years. Erek E, Süleymanlar G, Serdengeçti K: Nephrology, dialysis and transplantation in Turkey. Kalantar-Zadeh K, Golan E, Shohat T, et al: Survival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity. Counil É, Cherni N, Kharrat M, et al: Trends of incident dialysis patients in Tunisia between 1992 and 2001. Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, et al: Changing epidemiology of end-stage renal disease in last 10 years in Iran. Batieha A, Abdallah S, Maghaireh M, et al: Epidemiology and cost of haemodialysis in Jordan. Barbari A, Stephan A, Masri M, et al: Consanguinity-associated kidney diseases in Lebanon: an epidemiological study. Finer G, Shalev H, Landau D: Genetic kidney diseases in the pediatric population of southern Israel. International Society of Nephrology Global Outreach Research and Prevention-awarded projects. Vivante A, Afek A, Frenkel-Nir Y, et al: Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. Mahdavi-Mazdeh M, Saeed Hashemi Nazri S, Hajghasemi E, et al: Screening for decreased renal function in taxi drivers in Tehran, Iran. Tohidi M, Hasheminia M, Mohebi R, et al: Incidence of chronic kidney disease and its risk factors: results of over 10 year follow up in an Iranian cohort. Tuglular S, Yalcinkaya F, Paydas S, et al: A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Tanzer F, Ozgur A, Bardakci F: Type I cystinuria and its genetic basis in a population of Turkish school children. Zlotogora J: Molecular basis of autosomal recessive diseases among the Palestinian Arabs. Cohen T, Vardi-Saliternik R, Friedlander Y: Consanguinity, intracommunity and intercommunity marriages in a population sample of Israeli Jews. Al-Eisa A, Naseef M, Al-Hamad N, et al: Chronic renal failure in Kuwaiti children: an eight-year experience. Kazancioglu R, Ecder T, Altintepe L, et al: Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience. Frishberg Y, Feinstein S, Rinat C, et al: the heart of children with steroid-resistant nephrotic syndrome: is it all podocin Landau D, Oved T, Geiger D, et al: Familial steroid-sensitive nephrotic syndrome in Southern Israel: clinical and genetic observations. Frishberg Y, Rinat C, Shalata A, et al: Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Harambat J, Fargue S, Acquaviva C, et al: Genotype-phenotype correlation in primary hyperoxaluria type 1: the p. Topaloglu R, Vilboux T, Coskun T, et al: Genetic basis of cystinosis in Turkish patients: a single-center experience. Vivante A, Lotan D, Pode-Shakked N, et al: Familial autosomal recessive renal tubular acidosis: importance of early diagnosis. Aleem A: Renal abnormalities in patients with sickle cell disease: a single center report from Saudi Arabia. Eliakim M, Levy M, Ehrenfeld M: Recurrent polyserositis (familial Mediterranean fever), Amsterdam, 1981, Elsevier-North Holland Biomedical Press. Mohammadnejad L, Farajnia S: Mediterranean fever gene analysis in the Azeri Turk population with familial Mediterranean fever: evidence for new mutations associated with disease. Lotan D, Yoskovitz G, Bisceglia L, et al: A combined approach to the molecular analysis of cystinuria: from urinalysis to sequencing via genotyping. Sidi R, Levy-Nissenbaum E, Kreiss I, et al: Clinical manifestations in Israeli cystinuria patients and molecular assessment of carrier rates in Libyan Jewish controls. Raas-Rothschild A: Pediatrics: implementing the promise of early intervention for Fabry disease. Bahat H, Dinour D, Ganon L, et al: Non-urate transporter 1-related renal hypouricemia and acute renal failure in an IsraeliArab family. Jahanzad I, Amoueian S, Attaranzadeh A: Familial lecithincholesterol acyltransferase deficiency. Al-Haggar M: Cystinosis as a lysosomal storage disease with multiple mutant alleles: phenotypic-genotypic correlations. Al-Haggar M, Bakr A, Tajima T, et al: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: unusual clinical associations and novel claudin16 mutation in an Egyptian family. Ait-Idir D, Khilan A, Djerdjouri B, et al: Spectrum of mutations and carrier frequency of familial Mediterranean fever gene in the Algerian population. Brik R, Shinawi M, Kepten I, et al: Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Langevitz P, Zemer D, Livneh A, et al: Protracted febrile myalgia in patients with familial Mediterranean fever. Mattit H, Joma M, Al-Cheikh S, et al: Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype-genotype correlation. Medlej-Hashim M, Rawashdeh M, Chouery E, et al: Genetic screening of fourteen mutations in Jordanian familial Mediterranean fever patients. Settin A, El-Baz R, Abd Rasool M, et al: Clinical and molecular diagnosis of familial Mediterranean fever in Egyptian children. Shinawi M, Brik R, Berant M, et al: Familial Mediterranean fever: high gene frequency and heterogeneous disease among an IsraeliArab population. Solak M, Yildiz H, Koken R, et al: Analysis of familial Mediterranean fever gene mutations in 202 patients with familial Mediterranean fever. Sohar E, Gafni J, Pras M, et al: Familial Mediterranean fever: a survey of 470 cases and review of the literature. Shohat M, Magal N, Shohat T, et al: Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Touitou I, Sarkisian T, Medlej-Hashim M, et al: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Tunca M, Tankurt E, Akbaylar Akpinar H, et al: the efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Tweezer-Zaks N, Rabinovich E, Lidar M, et al: Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. Tunca M, Akar S, Soyturk M, et al: the effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Ozgocmen S, Ozcakar L, Ardicoglu O, et al: Familial Mediterranean fever responds well to infliximab: single case experience. Belkhir R, Moulonguet-Doleris L, Hachulla E, et al: Treatment of familial Mediterranean fever with anakinra. Moser C, Pohl G, Haslinger I, et al: Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Celik A, Saglam F, Dolek D, et al: Outcome of kidney transplantation for renal amyloidosis: a single-center experience. Keven K, Sengul S, Kutlay S, et al: Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Heering P, Hetzel R, Grabensee B, et al: Renal transplantation in secondary systemic amyloidosis.

Vanhorebeek I symptoms internal bleeding trileptal 150 mg buy with visa, Langouche L symptoms vaginitis 150 mg trileptal buy visa, Van den Berghe G: Endocrine aspects of acute and prolonged critical illness symptoms iron deficiency order trileptal visa. Disthabanchong S medicine 5277 generic trileptal 300 mg buy, Treeruttanawanich A: Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease treatment uterine cancer purchase trileptal online from canada. Chonchol M, Lippi G, Salvagno G, et al: Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Wuhl E, Schaefer F: Effects of growth hormone in patients with chronic renal failure: experience in children and adults. Garibotto G, Russo R, Sofia A, et al: Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. Haffner D, Schaefer F, Nissel R, et al: Effect of growth hormone treatment on the adult height of children with chronic renal failure: German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Hokken-Koelega A, Mulder P, De Jong R, et al: Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Feldt-Rasmussen B, Lange M, Sulowicz W, et al: Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. Guebre-Egziabher F, Juillard L, Boirie Y, et al: Shortterm administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. Feld S, Hirschberg R: Growth hormone, the insulin-like growth factor system, and the kidney. Yavuz D, Topcu G, Ozener C, et al: Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy. Bommer J, Ritz E, del Pozo E, et al: Improved sexual function in male haemodialysis patients on bromocriptine. Mejia-Rodriguez O, Alvarez-Aguilar C, Ledesma-Ramirez M, et al: Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Degli Esposti E, Sturani A, Santoro A, et al: Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Si J, Ge Y, Zhuang S, et al: Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Stehman-Breen C, Anderson G, Gibson D, et al: Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al: the benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Simon J, Braunstein G, Nachtigall L, et al: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. Maric C, Sandberg K, Hinojosa-Laborde C: Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. Catanuto P, Doublier S, Lupia E, et al: 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Iwashima F, Yoshimoto T, Minami I, et al: Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Fukui M, Kitagawa Y, Kamiuchi K, et al: Low serum dehydroepiandrosterone sulfate concentration is a predictor for deterioration of urinary albumin excretion in male patients with type 2 diabetes. Kawano H, Yasue H, Kitagawa A, et al: Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al: Endometrial morphology and pituitary-gonadal axis dysfunction in women of reproductive age undergoing chronic haemodialysis-a multicentre study. Rammohan M, Kalantar-Zadeh K, Liang A, et al: Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. Monfared A, Heidarzadeh A, Ghaffari M, et al: Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. Vita G, Bellinghieri G, Trusso A, et al: Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kyriazis J, Tzanakis I, Stylianou K, et al: Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. Fukata J, Imura H, Nakao K: Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function. Canguven O, Aykose G, Albayrak S, et al: Efficacy of testosterone gel in the treatment of erectile dysfunction in hypogonadal hemodialysis patients: a pilot study. Ji H, Menini S, Mok K, et al: Gonadal steroid regulation of renal injury in renal wrap hypertension. Haring R, Nauck M, Volzke H, et al: Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Molinari C, Battaglia A, Grossini E, et al: the effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. Johal M, Levin A: Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease. Dusilova-Sulkova S: Vitamin D metabolism and vitamin D traditional and nontraditional, target organs: implications for kidney patients. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al: Oral active vitamin D is associated with improved survival in hemodialysis patients. Dialysis therapy itself is also associated with neurologic complications, including dialysis dysequilibrium, a syndrome of delirium associated with the initiation of dialysis therapy, and dialysis dementia, a progressive disorder linked to aluminum toxicity. Stroke rates are increased 6- to 10-fold and stroke mortality 2- to 3-fold in patients on dialysis. This article reviews the epidemiology, pathophysiology, and treatment approach for stroke, disorders of cognitive function and sleep, and neuropathy in patients with kidney disease. Symptoms are typically unilateral, and consciousness is generally preserved except in the case of some posterior circulation strokes. Men and whites are reported to have a higher incidence of large artery atherosclerosis as compared to women and blacks, respectively. Intracerebral hemorrhage is most frequently attributed to hypertension, amyloid angiopathy, septic embolism, mycotic aneurysm, and bleeding diatheses, while subarachnoid hemorrhage is most often due to rupture of an arterial aneurysm or vascular malformation. Incident Dialysis Population (N = 176) Case Fatality Rate (%) 28 29 36 17 41 19 90 U. In addition, kidney disease may directly contribute to cerebrovascular disease through a number of novel mechanisms listed in Table 59. In the general population, stroke risk doubles for each 20 mm Hg increase in systolic blood pressure or 10 mm Hg increase in diastolic blood pressure above 115/75 mm Hg. The presence of nonvalvular atrial fibrillation increases the risk for stroke by 2. In a later study of 30,000 black and white adults in the United States, albuminuria was associated with an increased risk for incident stroke among blacks but not among whites. This relationship was independent of traditional stroke risk factors and present at levels of albuminuria below 30 mg/g. These associations appear to be mediated in part by blood pressure, as higher sodium intake tends to increase blood pressure in a dose-dependent manner, while higher potassium intake blunts the pressor effects of sodium. Even absent intradialytic hypotension, hemodialysis has been shown to cause cerebral hypoperfusion and may predispose to stroke. Overcorrection of anemia, especially in the setting of ultrafiltration, may lead to vascular stasis and thrombosis. Conversely, anticoagulation used for hemodialysis has also been speculated to contribute to hemorrhagic stroke risk during dialysis. Some studies note an increased risk for stroke during or immediately after hemodialysis treatments,13 and one study found an increased rate of stroke during the months immediately before and after dialysis initiation compared to the prior year. Similarly, there is a paucity of data regarding dialysis modality and stroke risk. Thus other indications should be taken into account when choosing initial therapy. Nonstatin lipidlowering agents such as niacin or gemfibrozil appear to have similar benefits as in the general population,81 though there are fewer data regarding use of these agents for stroke prevention. In the Die Deutsche Diabetes Dialyse Studie (4D study) of 1255 subjects with type 2 diabetes on maintenance hemodialysis, atorvastatin resulted in no difference in the primary cardiovascular composite end point as compared with placebo, despite lowering low-density lipoprotein cholesterol by an average of 42%. Combination therapy reduces the rate of recurrent stroke by 23% to 38% when compared to either agent alone or to placebo. Aspirin plus dipyridamole may be considered in high-risk patients, and clopidogrel may be considered for those intolerant to aspirin or with a recent acute coronary syndrome or stenting. Presentation with severe headache, vomiting, coma, a systolic blood pressure above 220 mm Hg, or history of warfarin use is associated with a higher likelihood of hemorrhage,122 but symptoms alone do not have sufficient diagnostic accuracy, and brain imaging is warranted to definitively distinguish hemorrhagic stroke from ischemic stroke. Timing of symptom onset, history of recent medical events (especially any history of trauma, surgery, or cardiovascular events), and use of antiplatelet agents or anticoagulants should be ascertained. The National Institutes of Health Stroke Scale can be used to estimate prognosis and determine the risk for hemorrhage with thrombolytic therapy, although it should be recognized that the scale has not been validated in patients on dialysis and therefore may underestimate hemorrhage risk. Intravenous contrast media administration is usually unnecessary for acute stroke evaluation but in some cases may be indicated if there is a high suspicion for brain tumors or infection. In these cases the risk for radiocontrast media­associated nephropathy must be weighed against the potential benefits, and prophylactic measures should be considered (see Chapter 28). For intravenous radiocontrast media administration, this should include administration of intravenous saline or bicarbonate before the procedure. For gadolinium administration, this should include minimization of the contrast media volume and consideration for immediate postprocedure hemodialysis in patients with vascular access. While there are theoretical reasons to treat hypertension following acute stroke, overly aggressive treatment of hypertension may lead to reduced perfusion and infarct expansion. In patients who are not candidates for thrombolytic therapy, consensus guidelines recommend blood pressure lowering for systolic blood pressure above 220 mm Hg or diastolic blood pressure above 120 mm Hg, or if there is other evidence for end-organ damage. The timing of hemodialysis treatments in the setting of acute stroke should be individualized based on consideration of fluid and metabolic control. Delirium is typically precipitated by an acute or subacute event such as a neurologic disorder, infection, electrolyte disorder, or intoxication (Table 59. It is characterized by lethargy and confusion in early stages and can progress to seizures and/or coma. Electroencephalographic abnormalities correspond with clinical symptoms and improve with treatment of uremia. While the available studies report white matter lesions suggestive of small vessel cerebrovascular disease (see previous section), it is unclear whether these pathologic abnormalities play a role in the development of uremic encephalopathy since most studies did not conduct simultaneous neurophysiologic or neuropsychiatric testing. Studies contrasting animal models of uremic encephalopathy in acute kidney injury with hepatic encephalopathy have demonstrated an increase in brain inflammation in conjunction with an increase in vascular permeability in uremic encephalopathy. Alternatively, the retention of uremic solutes may trigger both the inflammatory reaction and neuronal dysfunction. A large number of solutes are retained in uremia (Chapter 54), and several may have direct neurotoxicity or contribute indirectly to the pathogenesis of uremic encephalopathy by altering the blood-brain barrier. For example, the guanidine compounds are low-molecular-weight solutes with deleterious effects on immune and neurologic function in vivo. It is most likely to occur in pediatric or older adult patients, patients with severe azotemia, and patients undergoing high-efficiency hemodialysis; however, it has also been reported in patients undergoing peritoneal dialysis and maintenance hemodialysis. Pathophysiology the clinical features of dialysis dysequilibrium syndrome are primarily attributable to brain edema, although the nature and cause of the edema remain uncertain. While aluminum-based phosphate binders were often blamed for this syndrome, the aluminum moiety is so inefficiently absorbed, only parenteral exposure was likely relevant. This entity has various names in the literature, including "mild cognitive impairment," "subclinical dementia," "residual syndrome,"162 and "chronic dialysis-dependent encephalopathy," reflecting an unknown but probable multifactorial origin. Nevertheless, with proper instruction and follow-up, modest dietary protein restriction may be appropriate in certain settings. Epidemic forms occur in geographic clusters and are strongly associated with aluminum contamination of dialysate. The relation of aluminum intoxication to the sporadic and childhood forms of dialysis dementia is less clear. Some early studies revealed an increase in brain aluminum content 11-fold higher than in healthy persons and 3- to 4-fold higher than in patients requiring hemodialysis without dementia165 and speculated that use of aluminum-containing phosphate binders might be involved. Symptoms may be exacerbated by hemodialysis or by administration of deferoxamine or desferrioxamine, presumably due to mobilization and redistribution of tissue aluminum into the brain. If aluminum intoxication is confirmed, the dialysate should be checked for aluminum contamination, and any other sources of parenteral aluminum exposure should be explored. Chelation therapy is indicated despite the caveats noted earlier because there is no other effective method for removal of aluminum. Support for the "uremic solute" hypothesis comes from studies demonstrating improvement in cognitive function among children and middle-aged adults who undergo transplantation compared to matched patients on the transplant waiting list. Some, though not all, studies have found that cognitive function varies according to the weekly dialysis schedule among patients requiring hemodialysis, but not among patients requiring peritoneal dialysis. One study reported reduced cerebral blood flow among patients requiring hemodialysis compared to healthy controls; however, intradialytic measurements were not reported. In a randomized clinical trial of frequent in-center hemodialysis, frequent dialysis resulted in no significant improvement in most cognitive domains relative to thrice-weekly hemodialysis over the course of 12 months, including in the primary and secondary cognitive function measures. Improvements were noted in domains of memory and verbal fluency, but the significance of these findings remains to be determined. A trial of frequent home-based nocturnal hemodialysis found no improvement in several cognitive domains; however, these negative results are possibly confounded by sleep disturbance. The value of routine screening for dementia in the general population is controversial. A large number of screening tests are available with a range of administration times and diagnostic accuracy; thus, there is no single best screening test. Other cognitive tests that can be administered in 5 minutes or less, such as the clock-drawing task, the Mini-Cog (consisting of the clock-drawing task plus uncued recall of three words), or the Short Portable Mental Status Questionnaire, have similar performance characteristics in the general population. Neuropsychologic testing on a nondialysis day can be useful if the diagnosis is uncertain or when testing is performed to establish capacity or potential reversibility. In addition to cognitive function testing, laboratory testing for vitamin B12 deficiency and hypothyroidism is recommended for all patients with suspected dementia. There are conflicting recommendations from guideline panels regarding the routine use of structural neuroimaging in the work-up of chronic cognitive impairment. Further, the extent to which transplantation reverses cognitive impairment, especially in frail patients with coexisting illness, is uncertain.

Buy generic trileptal pills. Clinical depression | signs of depression | depression symptoms.

The incidence of fusion anomalies is estimated to be approximately 1 per 600 infants treatment 8th march buy trileptal pills in toronto. The reported incidence of horseshoe kidney based upon data from birth defect registries varies from 0 symptoms kidney order trileptal 600 mg fast delivery. In the majority of affected patients symptoms 5dp5dt order trileptal toronto, congenital renal malformations occur as sporadic events medications during breastfeeding buy 600 mg trileptal with amex. In approximately 30% of affected individuals medicine vs dentistry buy trileptal without a prescription, these malformations occur as part of a multiorgan genetic syndrome. Renal­urinary tract malformations and extrarenal malformations can go unrecognized unless a careful phenotypic examination is performed. Over 200 distinct genetic syndromes feature some type of kidney and urinary tract malformation. Incomplete penetrance with variable expressivity is frequent in affected families. In probands with bilateral renal agenesis or bilateral renal dysgenesis and without evidence of a genetic syndrome or a family history, 9% of first-degree relatives were shown by ultrasonography to have some type of malformation in the kidney and/or lower urinary tract. The incidence of renal and urinary tract malformations identified in fetal ultrasonography is 0. These anomalies include vesicoureteral reflux (25%), ureteropelvic junction obstruction (11%), and ureterovesical junction obstruction (11%). Complete or partial duplication of the renal collecting system is the most common congenital anomaly of the urinary tract. Unilateral renal agenesis has been reported with a prevalence of 1 per1000 autopsies. Briefly summarized, formation of the human kidney is initiated at 5 weeks of gestation in the human when the ureteric duct is induced to undergo lateral outgrowth from the wolffian duct and to invade the adjacent metanephric mesenchyme. The ureteric bud then undergoes repetitive branching events, so termed because each event consists of expansion of the advancing ureteric bud branch at its leading tip, division of the ampulla resulting in formation of new branches, and elongation of the newly formed branches. Beginning with the tenth- to eleventh-branch generation, the pattern of branching becomes terminally bifid. During branching morphogenesis 65,000 collecting ducts are formed, both as cortical and medullary collecting ducts, a process that is essential to the function of the mature kidney. During the latter stages of kidney development, tubular segments formed from the first five generations of ureteric bud branching undergo remodeling to form the kidney pelvis and calyces. The position at which the ureteric bud arises from the wolffian duct relative to the metanephric mesenchyme is critical to the nature of the interactions between the ureteric bud and the metanephric mesenchyme. Mackie and Stephens postulated that an abnormal position of the ureteral orifice in the bladder is associated with vesicoureteral reflux in humans. Interestingly, the domain of Gdnf expression is expanded anteriorly in these mice, which suggests that loss of inhibition of Gdnf expression by Robo2 dependent signaling expands the domain of Gdnf expression and results in ectopic ureteric budding. The number of ureteric bud branches elaborated is considered to be a major determinant of final nephron number because each ureteric bud branch tip induces a discrete subset of metanephric mesenchyme cells to undergo nephrogenesis (see Chapter 1). Regulation of ureteric branch number has been informed by complementary studies in humans and mice. The most common finding is an optic disc pit associated with vascular abnormalities and cilioretinal arteries, with mild visual impairment limited to blind spot enlargement. It encodes a transcription factor that belongs to the paired box family of homeotic genes. In 1995, Sanyanusin and colleagues reported heterozygous mutations in two families with renal-coloboma syndrome. Decreased ureteric branch number and nephron number are rescued by inhibition of apoptosis in the ureteric lineage. In the metanephric mesenchyme, Sall1, Eya1, and Six1 positively control Gdnf expression. Sall1, a member of the Spalt family of transcriptional factors,47 is expressed in the metanephric mesenchyme before and during ureteric bud invasion. Mutational inactivation of Sall1 in mice causes renal agenesis or severe dysgenesis and a marked decrease in Gdnf expression. Within the same family a given mutation may be associated with renal malformation in some individuals, but not in others. Pallister-Hall syndrome is an autosomal dominant multiorgan disorder characterized by multiple renal abnormalities, including agenesis or dysplasia, hypoplasia, and hydronephrosis. During kidney development in mice, Tcf2 is expressed in the wolffian duct, ureteric bud, comma- and S-shaped bodies, and proximal and distal tubules. Mutations in angiotensinogen and in the angiotensinogen type 1 receptor genes occur much less frequently. Low birth weight or intrauterine growth restriction is generally considered to be due to a suboptimal in utero environment. Here, the fetal kidney is particularly susceptible, which leads to reduced nephron number. In humans intrauterine growth restriction is most often due to uteroplacental insufficiency and maternal undernutrition. The expression of Gdnf and Wnt11, both of which are required during ureteric branching was reduced, consistent with a decrease in nephrogenesis. Infants with simple renal hypoplasia or a moderate to severe degree of hypodysplasia exhibit renal insufficiency. A more subtle deficiency in nephron number has been associated with adult-onset hypertension. Growth of renal tubules and expansion of glomerular cross-sectional area in utero and after birth is critical to renal functional capacity. The developmental maturation of renal structures is discussed in this chapter in the context of their functions. Illustrative examples are provided for how abnormal differentiation, growth, and maturation in the malformed kidney can limit these functions. Existing knowledge has been generated, for the most part, from the study of maturing preterm and term animals. In contrast, very few data have been derived from the study of animals, such as mutant mice, with renal malformation. Thus interpretation of physiologic abnormalities in humans and experimental animals with renal malformation is largely an extrapolation from developmental studies in experimental animals with normal kidney development. The responsiveness of collecting duct cells to vasopressin is limited in newborns. Normal newborn infants are limited in their capacity to respond to sodium restriction by reducing urinary sodium excretion. Interruption of tubule generation, differentiation, and growth, which are hallmark features of renal dysplasia, contributes to an exaggerated limitation in the capacity to absorb sodium in affected infants and children. The proximal tubule exhibits dramatic growth and maturation during renal development. If the bladder wall is thick, urethral obstruction such as posterior urethral valves in a male fetus may be present. By 20 weeks of gestation and thereafter, fetal urine is the primary source of amniotic fluid volume. Urine levels of sodium and 2microglobulin decrease with increasing gestational age, and urine osmolality increases. Other associated urologic anomalies include obstruction of the ureteropelvic junction in 6% to 7% and ureterovesical junction in 11% to 18% of patients. A screening antenatal ultrasound examination is recommended between 16 and 20 weeks of gestation, by which time renal anatomy can be imaged with considerable definition and anomalies can be detected with a sensitivity of approximately 80%. Visualization of ureters may be indicative of ureteric or bladder obstruction or vesicoureteral reflux. Bilateral dysplasia is likely to be diagnosed earlier than unilateral dysplasia, especially if oligohydramnios is present. Infants with bilateral dysplasia may demonstrate impaired renal function shortly after birth. Associated urinary tract abnormalities include hydronephrosis, a duplicated collecting system, megaureter, ureteral stenosis, and vesicoureteral reflux. The multicystic dysplastic kidney is identified by ultrasonography as a large cystic nonreniform mass in the renal fossa and by palpation as a flank mass. In unilateral multicystic dysplastic kidney, associated contralateral abnormalities occur in 25% of cases and can include rotational or positional anomalies, renal hypoplasia, vesicoureteric efflux, and ureteropelvic junction obstruction. At 2 years of age, an involution in size can be detected by ultrasonography in up to 60% of the affected kidneys. A double collecting system is thought to result from duplication of the ureteric bud, whereby the superior bud is associated with the upper renal pole and the inferior bud with the lower renal pole. In complete duplication the kidney has two separate pelvicalyceal systems and two ureters. In boys, insertion can occur in the posterior urethra, ejaculatory ducts, or epididymis; in girls, insertion can occur in the vagina or uterus. Ectopic insertion of the ureter can result in obstruction or vesicoureteral reflux. Depending upon the location of the ectopic insertion, incontinence also may be present. In these cases the kidney has two separate pelvicalyceal systems with either a single ureter or two ureters that unite before insertion into the bladder. Rapid caudal growth during embryogenesis results in migration of the developing kidney from the pelvis to the retroperitoneal renal fossa. With ascension comes a 90-degree rotation from a horizontal to a vertical position with the renal hilum finally directed medially. It most commonly lies over the pelvic brim or in the pelvis and is termed a pelvic kidney. Less commonly, the kidney may lie on the contralateral side of the body, a state that is termed crossed ectopy without fusion. Although affected individuals are generally asymptomatic and are identified during an imaging study performed for some other indication, some patients develop symptoms due to complications, such as infection, renal calculi, and urinary obstruction. The most frequent of these is vesicoureteral reflux, which occurs in 20% of crossed renal ectopy, 30% of simple renal ectopy, and 70% in bilateral simple renal ectopy. The horseshoe kidney differs from crossed fused renal ectopy, which usually involves abnormal movement of only one kidney across the midline with fusion of the contralateral noncrossing kidney. In more than 90% of cases of horseshoe kidney, fusion occurs at the lower poles; as a result two separate excretory renal units and ureters are maintained. Fusion is thought to occur before the kidneys ascend between the fourth and ninth week of gestation from the pelvis to their normal dorsolumbar position. If large portions of the renal parenchyma fuse, the fusion anomaly loses its horseshoe appearance and appears as a flattened disk or lump kidney. The blood supply of the fused kidney is variable and may come from the iliac arteries, aorta, and at times the hypogastric and middle sacral arteries. Some, however develop urinary tract obstruction, which presents with loin pain, hematuria, and may be associated with urinary tract infections due to urinary stasis or vesicoureteric reflux. Obstruction resulting in urinary stasis and complicating urinary tract infection have been thought to be the major contributing factors to stone formation. In most cases the ectopic kidney is positioned inferiorly to the contralateral kidney. Most patients with crossed fused ectopy are asymptomatic and are detected coincidentally, often by antenatal ultrasonography. As is true in patients with horseshoe kidney, most patients have an excellent prognosis without need for intervention. In some cases, complications can occur, including obstructive uropathy due to extrinsic ureteric compression by aberrant blood vessels or ureteropelvic junction obstruction, renal calculi, urinary tract infection, and vesicoureteral reflux. Coordinated consultation among professionals in the disciplines of obstetrics, pediatric nephrology, pediatric urology, and neonatology is critical. The level of certainty regarding the severity of the diagnosis and prognosis has a major impact on decision making during pregnancy and in the immediate postnatal period. Intervention in utero has been designed to (1) reduce renal damage arising from urinary tract obstruction and (2) rescue pulmonary development in the face of urinary tract obstruction and oligohydramnios. In contrast, insertion of a bladder­amniotic cavity shunt in the fetus with obstruction below the bladder neck can rescue oligohydramnios and pulmonary hypoplasia. After delivery a detailed history and careful physical examination should be performed in all infants with an antenatally detected renal malformation. In newborns with bilateral renal malformation, a solitary malformed kidney, or a history of oligohydramnios, abdominal ultrasonography is recommended within the first 24 hours of life because an intervention such as decompression of the bladder with a transurethral catheter may be required. In these infants renal ultrasonography is generally performed after 48 hours of age and within the first week of life. Ultrasonographic examination before 48 hours of age may not detect collecting system dilation because a newborn is in a relatively volume-contracted state during this period of time. The serum creatinine concentration at birth is similar to that in the mother (usually 1. Thus serum creatinine concentration should be measured after the first 24 hours of life. The presence of vesicoureteral reflux or some other collecting system abnormality in the normal contralateral kidney places children with unilateral renal dysplasia at increased risk for long-term sequelae of renal scarring from recurrent urinary tract infection. The prognosis for a patient with renal dysplasia depends on whether there is unilateral or bilateral disease. In general, the long-term outcome of unilateral renal dysplasia is excellent, particularly if there is a normal contralateral kidney. Over time, as mentioned previously, a multicystic dysplastic kidney is gradually reduced in size to the point that the kidney eventually cannot be detected through noninvasive imaging. Renal ultrasonography is generally recommended at intervals of 3 months for the first year of life and then every 6 months up to involution of the mass, or at least up to 5 years.

References

• Croxton TL, Weinmann GG, Senior RM, et al. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:838-44.
• Brugman F, Wokke JHJ, Vianney de Jong JM, Franssen H, Faber CG, Van den Berg LH. Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology.2005;64(10):1778-1779.
• Slichter SJ. Platelet transfusions: a constantly evolving therapy. Thromb haemostas. 1991;66:178-88.
• Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365: 130-134.
• Soliman MG, Ansara S, Laberge R: Caudal anaesthesia in paediatric patients, Can Anaesth Soc J 25(3):226n229, 1978.